News for Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here.

The United States Patent and Trademark Office's Patent Trial and Appeal Board has decided to review the patents held by Halozyme (HALO) at the request of Merck.

Wells Fargo analyst Mohit Bansal has highlighted a recent development where the Patent Trial and Appeal Board (PTAB) has initiated a patent review against Haloz

Looking into the current session, Halozyme Therapeutics Inc. HALO shares are trading at $53.85, after a 1.05% drop. Over the past month, the stock decreased by ...

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Evolv Technologies Holdings, Inc. EVLV rose sharply during Friday's s...

Halozyme Therapeutics (HALO) has received an analyst rating update from Morgan Stanley. The analyst, Vikram Purohit, has downgraded the stock from "Overweight"

Key Takeaways: Halozyme Therapeutics downgraded by Morgan Stanley, raising concerns over potential Medicare negotiations. Despite the downgrade, analysts

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]

Morgan Stanley has revised its rating for Halozyme (HALO), moving it from Overweight to Equal Weight. The bank also adjusted the stock's price target from $73 t

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday. The Dow traded down 0.49% to 42,203.63 while th...

Halozyme Therapeutics (HALO) saw its stock tumble significantly on Tuesday after Leerink downgraded its rating from Market Perform to Underperform, setting a ne

Key Takeaways: Halozyme Therapeutics (HALO) downgraded to "Underperform" by Leerink Partners. Potential revenue challenges due to changes in Medicare pri

I'll complete the article based on the information gathered so far.

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

After cardiovascular disease, cancer is the second most common cause of mortality worldwide.

We recently published a list of Why These 10 Stocks Soared Today.

Total Revenue: Increased 35% year-over-year to $265 million.Royalty Revenue: Increased 39% to $168 million.Adjusted EBITDA: Increased to $162 million, represen

May 06, 2025 / 08:30PM GMTOperator Good afternoon. My name is Bailey, and I'll be your conference operator today. At this time, I would like to welcome everyone